AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14629104 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors
Number of subjects: 0
Study 10998949 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-matched intervention involving personality-specific motivational and coping skills training
Number of subjects: 198
Study 10998949 — intervention group
Group type: COMPARATOR
Intervention: Motivational control intervention involving a motivational film and a supportive discussion with a therapist
Number of subjects: 198
Study 10998949 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-mismatched intervention targeting a theoretically different personality profile
Number of subjects: 198
Study 8869535 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable skin dressing (SPD) applied to the chest, abdomen, and back.
Number of subjects: 39
Study 8869535 — intervention group
Group type: COMPARATOR
Intervention: Control (no dressing applied).
Number of subjects: 39
Study 8869535 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable skin dressing (SPD).
Number of subjects: 39
Study 1798594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein supplementation
Number of subjects: 19
Study 1798594 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 6134535 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.03 mg kg‐1
Number of subjects: 40
Study 6134535 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.057 mg kg‐1
Number of subjects: 40
Study 6134535 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.042 mg kg‐1
Number of subjects: 40
Study 6134535 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.08 mg kg‐1
Number of subjects: 40
Study 6134535 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 40
Study 6134535 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 40
Study 31820032 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) in ICUs with low prevalence of antibiotic resistance
Number of subjects: 3
Study 31820032 — intervention group
Group type: COMPARATOR
Intervention: Selective decontamination of the digestive tract (SDD) in ICUs with moderate-to-high prevalence of antibiotic resistance
Number of subjects: 3
Study 30545718 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery (ARBCCA)
Number of subjects: 200
Study 30545718 — intervention group
Group type: COMPARATOR
Intervention: Classic carotid endarterectomy with xenopericardial patch closure
Number of subjects: 200
Study 30545718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ARBCCA and classic CEA)
Number of subjects: 200
Study 28988232 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHD-HCO
Number of subjects: 30
Study 28988232 — intervention group
Group type: COMPARATOR
Intervention: CVVHD-STD
Number of subjects: 30
Study 25738786 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming mattress
Number of subjects: 484
Study 25738786 — intervention group
Group type: COMPARATOR
Intervention: Standard method of warming (heat-retaining caps, warmed intravenous and irrigation fluids, and warmed blankets)
Number of subjects: 484
Study 25738786 — intervention group
Group type: COMPARATOR
Intervention: Standard method of warming
Number of subjects: 484
Study 23939292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B silicone hydrogel lenses (daily wear, monthly replacement)
Number of subjects: 240
Study 21320316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - informed their drinking will be assessed at baseline and again in one month (as in a cohort study design)
Number of subjects: 0
Study 21320316 — intervention group
Group type: COMPARATOR
Intervention: Group B - told the study is an intervention trial and they are in the control group
Number of subjects: 0
Study 21320316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - told the study is an intervention trial and they are in the intervention group
Number of subjects: 0
Study 19927175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 68
Study 19927175 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 68
Study 17237662 — intervention group
Group type: EXPERIMENTAL
Intervention: IA CRH (10 microg)
Number of subjects: 51
Study 17237662 — intervention group
Group type: EXPERIMENTAL
Intervention: IA CRH (10 microg) + naloxone (0.12 mg)
Number of subjects: 51
Study 17237662 — intervention group
Group type: COMPARATOR
Intervention: IA saline (isotonic) + IV CRH (10 microg)
Number of subjects: 51
Study 17237662 — intervention group
Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 51
Study 15566918 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin therapy
Number of subjects: 35
Study 15566918 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 11681501 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin/gentamicin eyedrops
Number of subjects: 123
Study 11681501 — intervention group
Group type: COMPARATOR
Intervention: gentamicin alone
Number of subjects: 123
Study 9761520 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO)
Number of subjects: 102
Study 9761520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with rhEPO)
Number of subjects: 102
Study 8659195 — intervention group
Group type: EXPERIMENTAL
Intervention: Running or swimming therapy (according to the stamina principle)
Number of subjects: 40
Study 8659195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine therapy (40‐60 mg/d)
Number of subjects: 40
Study 2258250 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg/day)
Number of subjects: 30
Study 2258250 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg/day)
Number of subjects: 30
Study 6947988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.035% alexidine mouthrinse
Number of subjects: 22
Study 6947988 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 22
Study 6947988 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study with 0.035% alexidine
Number of subjects: 22
Study 6947988 — intervention group
Group type: COMPARATOR
Intervention: In vitro study with 0.2% chlorhexidine
Number of subjects: 22
Study 31910861 — intervention group
Group type: EXPERIMENTAL
Intervention: SWATs (Studies Within A Trial)
Number of subjects: 0
Study 31910861 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 29685813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TOBI 300 mg)
Number of subjects: 51
Study 29685813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27987240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0
Study 27987240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27987240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5/10 mg
Number of subjects: 0
Study 27987240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 26278075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication during scenario encoding
Number of subjects: 0
Study 26278075 — intervention group
Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 0
Study 26278075 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told they were drinking alcohol
Number of subjects: 0
Study 26278075 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral details
Number of subjects: 0
Study 26278075 — intervention group
Group type: EXPERIMENTAL
Intervention: Central details
Number of subjects: 0
Study 24691799 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Fenofibrate 145 mg (simultaneous dosing)
Number of subjects: 85
Study 24691799 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Fenofibrate 145 mg (staggered dosing)
Number of subjects: 85
Study 24691799 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin only (evening)
Number of subjects: 85
Study 24691799 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Fenofibrate (both in evening)
Number of subjects: 85
Study 22978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaomian No. 3 (TM3)
Number of subjects: 61
Study 22978099 — intervention group
Group type: COMPARATOR
Intervention: Active immunotherapy using lymphocytes of spouses (Control)
Number of subjects: 61
Study 20089449 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 94370
Study 20089449 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 94370
Study 17204716 — intervention group
Group type: EXPERIMENTAL
Intervention: CT cancer screening
Number of subjects: 0
Study 17204716 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT cancer screening
Number of subjects: 0
Study 17204716 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body PET/CT for diagnosing, staging, and restaging cancer
Number of subjects: 0
Study 17204716 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body PET/CT for surveillance of selected groups of patients
Number of subjects: 0
Study 15604959 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lymphoscintigraphy (15 minutes to 4 hours after radionuclide injection)
Number of subjects: 15
Study 15604959 — intervention group
Group type: COMPARATOR
Intervention: Delayed lymphoscintigraphy (18‐24 hours after radionuclide injection)
Number of subjects: 15
Study 12121799 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-PA (telephone-linked communication promoting moderate-intensity physical activity)
Number of subjects: 298
Study 12121799 — intervention group
Group type: COMPARATOR
Intervention: TLC-Eat (automated intervention promoting healthy eating)
Number of subjects: 298
Study 9236626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild diabetic polyneuropathy
Number of subjects: 47
Study 9236626 — intervention group
Group type: COMPARATOR
Intervention: Other polyneuropathies
Number of subjects: 47
Study 9236626 — intervention group
Group type: COMPARATOR
Intervention: Vasculitic polyneuropathy
Number of subjects: 47
Study 9236626 — intervention group
Group type: COMPARATOR
Intervention: Severe diabetic polyneuropathy
Number of subjects: 47
Study 9236626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild diabetic polyneuropathy (10 patients)
Number of subjects: 47
Study 7864906 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis through a sideport incision
Number of subjects: 28
Study 7864906 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 28
Study 3118342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fast neutron and photon irradiation (mixed-beam)
Number of subjects: 91
Study 3118342 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon irradiation alone
Number of subjects: 91
Study 29513132 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Playtime Intervention (FPI) for 12 weeks
Number of subjects: 70
Study 29513132 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 70
Study 27020071 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 106
Study 27020071 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Medical Care (EMC)
Number of subjects: 106
Study 25276762 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 50
Study 25276762 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 22738947 — intervention group
Group type: EXPERIMENTAL
Intervention: Low O2 saturation target range (85%-89%)
Number of subjects: 115
Study 22738947 — intervention group
Group type: COMPARATOR
Intervention: High O2 saturation target range (91%-95%)
Number of subjects: 115
Study 20608357 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling anterior urethral stent
Number of subjects: 38
Study 20608357 — intervention group
Group type: COMPARATOR
Intervention: Urethral dilatation
Number of subjects: 38
Study 18452257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering the fasting plasma glucose (FPG) criteria for IFG from 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL)
Number of subjects: 7211
Study 18452257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering the FPG criterion for IFG
Number of subjects: 7211
Study 18452257 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with IFG (5.6‐7.0 mmol/L)
Number of subjects: 7211
Study 18452257 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with normal glucose tolerance (NGT)
Number of subjects: 7211
Study 18452257 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FPG for predicting the development of diabetes
Number of subjects: 7211
Study 15845691 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-TEA (Dextromethorphan 40 mg IM combined with TEA)
Number of subjects: 0
Study 15845691 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM-TEA (Chlorpheniramine maleate 20 mg combined with TEA)
Number of subjects: 0
Study 15845691 — intervention group
Group type: COMPARATOR
Intervention: CPM-GA (Chlorpheniramine maleate 20 mg with general anesthesia)
Number of subjects: 0
Study 12425755 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 5 microg/kg subcutaneously daily
Number of subjects: 413
Study 12425755 — intervention group
Group type: COMPARATOR
Intervention: leridistim 5 microg/kg subcutaneously daily
Number of subjects: 413
Study 12425755 — intervention group
Group type: COMPARATOR
Intervention: leridistim 10 microg/kg subcutaneously every other day alternating with placebo
Number of subjects: 413
Study 10509850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (0.8% polymer concentration)
Number of subjects: 70
Study 10509850 — intervention group
Group type: COMPARATOR
Intervention: Lower-molecular-weight hyaluronan (LMW HA) (1% polymer concentration)
Number of subjects: 70
Study 10509850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 70
Study 10509850 — intervention group
Group type: COMPARATOR
Intervention: Lower-molecular-weight hyaluronan (LMW HA)
Number of subjects: 70
Study 7571793 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 0
Study 7571793 — intervention group
Group type: COMPARATOR
Intervention: O-(beta-hydroxyethyl)-rutosides (HR)
Number of subjects: 0
Study 1857137 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized primary care system
Number of subjects: 0
Study 6140700 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐308 (10 mg)
Number of subjects: 8
Study 6140700 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐308 (20 mg)
Number of subjects: 8
Study 6140700 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazepam (30 mg)
Number of subjects: 8
Study 6140700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30736085 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided Radiofrequency Sacroplasty (RFS)
Number of subjects: 100
Study 30736085 — intervention group
Group type: COMPARATOR
Intervention: Cement Sacroplasty (CSP)
Number of subjects: 100
Study 29800026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus gel, 0.2%
Number of subjects: 62
Study 29800026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26999197 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Tomatoes (RT)
Number of subjects: 40
Study 26999197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato Sauce (TS)
Number of subjects: 40
Study 26999197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato Sauce with Olive Oil (TSOO)
Number of subjects: 40
Study 26999197 — intervention group
Group type: COMPARATOR
Intervention: Control (Sugar solution)
Number of subjects: 40
Study 23878109 — intervention group
Group type: EXPERIMENTAL
Intervention: Scutellaria lateriflora (350 mg) three times daily for two weeks
Number of subjects: 43
Study 23878109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 23878109 — intervention group
Group type: EXPERIMENTAL
Intervention: Scutellaria lateriflora (350 mg)
Number of subjects: 43
Study 22158682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin IPV (high D Ag)
Number of subjects: 500
Study 22158682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin IPV (middle D Ag)
Number of subjects: 500
Study 22158682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin IPV (low D Ag)
Number of subjects: 500
Study 22158682 — intervention group
Group type: COMPARATOR
Intervention: Trivalent OPV (control)
Number of subjects: 500
Study 22158682 — intervention group
Group type: COMPARATOR
Intervention: Conventional IPV (cIPV, control)
Number of subjects: 500
Study 21702264 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti HCV positive by ELISA
Number of subjects: 254
Study 17286522 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1460
Study 17286522 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 1460
Study 17286522 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 1460
Study 17286522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1460
Study 15926987 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 51
Study 15926987 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit
Number of subjects: 51
Study 12480850 — intervention group
Group type: EXPERIMENTAL
Intervention: Self help intervention (five self help booklets)
Number of subjects: 1527
Study 12480850 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control group)
Number of subjects: 1527
Study 12480850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1527
Study 9704834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% cream once daily
Number of subjects: 22
Study 9704834 — intervention group
Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05% cream twice daily
Number of subjects: 22
Study 9704834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (FP and CB)
Number of subjects: 22
Study 9345395 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Number of subjects: 72
Study 9345395 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Number of subjects: 72
Study 9345395 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 2565767 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (150 mg/day)
Number of subjects: 60
Study 2565767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 348406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone valerate cream (0.2 percent)
Number of subjects: 68
Study 348406 — intervention group
Group type: COMPARATOR
Intervention: Fluorinated beta-methasone valerate cream (0.1 percent)
Number of subjects: 68
Study 348406 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone cream (0.1 percent)
Number of subjects: 68
Study 348406 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream base
Number of subjects: 68
Study 27522059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inflammation z-score
Number of subjects: 1159
Study 27522059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin 3
Number of subjects: 1159
Study 27522059 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid P
Number of subjects: 1159
Study 27522059 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 1159
Study 27522059 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 1159
Study 25557807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-based weight loss program
Number of subjects: 234
Study 24371452 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperUlam
Number of subjects: 20
Study 24371452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21645117 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cellulose powder
Number of subjects: 53
Study 21645117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment assessment including self‐report questionnaires, interviews, and psychophysiological assessment
Number of subjects: 100
Study 19588513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment assessment
Number of subjects: 100
Study 17215608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking program (9 women)
Number of subjects: 19
Study 17215608 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking plus diet program (10 women)
Number of subjects: 19
Study 12768510 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 186
Study 12768510 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 186
Study 11079660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 320
Study 11079660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 9348547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 14
Study 9348547 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 14
Study 9348547 — intervention group
Group type: COMPARATOR
Intervention: Medication-free phase
Number of subjects: 14
Study 8406169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ursodeoxycholic acid
Number of subjects: 93
Study 8406169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 8406169 — intervention group
Group type: COMPARATOR
Intervention: High fibre, low refined carbohydrate diet
Number of subjects: 93
Study 3465375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Prostaglandin F2-alpha
Number of subjects: 45
Study 3465375 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic Prostaglandin F2-alpha
Number of subjects: 45